Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 466,430
  • Shares Outstanding, K 45,999
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.62
  • Number of Estimates 2
  • High Estimate -0.58
  • Low Estimate -0.66
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -12.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +102.40%
on 08/14/19
10.80 -6.11%
on 09/11/19
+4.97 (+96.13%)
since 08/13/19
3-Month
4.32 +134.72%
on 07/25/19
10.80 -6.11%
on 09/11/19
+4.88 (+92.78%)
since 06/13/19
52-Week
4.32 +134.72%
on 07/25/19
54.54 -81.41%
on 09/20/18
-37.81 (-78.85%)
since 09/13/18

Most Recent Stories

More News
Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders(1) that summarizes the evidence supporting the function of microdystrophin-associated...

SLDB : 10.14 (unch)
Will Solid Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Solid Biosciences.

SLDB : 10.14 (unch)
Sarepta Stock Falls as FDA Denies Approval to Golodirsen

The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

SLDB : 10.14 (unch)
SRPT : 86.00 (-2.25%)
BOLD : 31.74 (-0.28%)
PFE : 36.91 (-0.99%)
Solid Biosciences Surges on DMD Gene Therapy Study Amendments

Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.

SLDB : 10.14 (unch)
SRPT : 86.00 (-2.25%)
BOLD : 31.74 (-0.28%)
PFE : 36.91 (-0.99%)
Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update

- Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial -

SLDB : 10.14 (unch)
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.

SLDB : 10.14 (unch)
SRPT : 86.00 (-2.25%)
BMRN : 72.65 (-0.21%)
PFE : 36.91 (-0.99%)
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors

Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $60 million...

SLDB : 10.14 (unch)
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

SLDB : 10.14 (unch)
SRPT : 86.00 (-2.25%)
WVE : 23.94 (-0.66%)
PFE : 36.91 (-0.99%)
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

PTCT : 42.86 (-0.65%)
SLDB : 10.14 (unch)
SRPT : 86.00 (-2.25%)
PFE : 36.91 (-0.99%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB). Such...

SLDB : 10.14 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SLDB with:

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 10.69
1st Resistance Point 10.42
Last Price 10.14
1st Support Level 9.93
2nd Support Level 9.71

See More

52-Week High 54.54
Fibonacci 61.8% 35.36
Fibonacci 50% 29.43
Fibonacci 38.2% 23.50
Last Price 10.14
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar